Home > About Us > Board of Managers & Advisory Board

Board of Managers

C. Dean Maglaris, CEO, Chairman of the Board of Managers. Mr. Maglaris is an experienced senior executive in the pharmaceutical industry, having spent over 33 years with Pfizer Inc. in leadership positions in marketing, product and business development and general management. His experience covered the spectrum of major therapeutic areas in pharmaceuticals plus a wide array of medical device markets in the U.S. and worldwide. As Group Vice President and General Manager, he was instrumental in the development and launch of several products that became major successes, with several achieving annual sales in excess of $1.0 billion each. Mr. Maglaris has been a member of a number of associations, including the Pharmaceutical Research and Manufacturers of America and the Biotechnology Industry Organization. He is a past Trustee and Chair of the Board of Trustees of the University of Vermont, a past member and officer of the Board of Trustees of the New Canaan Country School and serves as Chariman of the Board of Directors of the AmeriCares Foundation. He holds a B.S. degree from the University of Vermont and an MBA from Northeastern University.



Steven G. Chrust, is founder and Senior Managing Partner of Centripetal Capital Partners (www.centricap.com) a private equity investment firm founded in 2004. He is also Founder and President of SGC Advisory Services, Inc., since 1991. Mr. Chrust serves on several boards, including as Chairman of APJeT, Inc. and IMCS. He is a member of the Association for Investment Management and Research and the New York Society of Securities Analysts. He has lectured at the Harvard Business School and testified before Congress concerning the break-up of AT&T, and before state public utility commissions on various regulatory matters. In 1994, he co-founded WinStar Communications, Inc., a facilities based local telecommunications provider utilizing fixed wireless technology and served as its Vice Chairman until the end of 1998. Mr. Chrust also served as Chairman of Worlds.com between 1999-2001. Mr. Chrust began his career in 1970, at Sanford C. Bernstein & Co., Inc., a financial institution handling more than $400 billion in client assets, currently known as AllianceBernstein. While at Bernstein, he was Director of Technology Research and ranked in the top tier of telecommunications analysts for more than a decade by Institutional Investor and ranked the #1 analyst in the sector for five consecutive years in their all-star ranking. Mr. Chrust is a graduate of Bernard M. Baruch College of the City University of New York and attended its business graduate school.



Alan W. Dunton, M.D., brings a depth and breadth of scientific and clinical/medical knowledge to the Board of Managers. Dr. Dunton has devoted his 35-year career to the discovery and development of new prescription and OTC drug products. He is a creative and visionary leader who has successfully developed and achieved approval of over 20 commercially successful Rx and OTC drugs. He has led major pharma R&D and Regulatory divisions as well as has been CEO/COO of both public and private biotechnology companies. He was the President and Managing Director of the Janssen Research Foundation - the R&D and Regulatory arm of the pharmaceuticals division at Johnson and Johnson. He has also been at Roche, Syntex, Novartis (as CIBA-GEIGY) and Purdue.

Dr. Dunton holds a M.D. from New York University School of Medicine, where he completed his residency in internal medicine. He was a Fellow in Clinical Pharmacology at the New York Hospital/Cornell University Medical Center. He is a diplomat of the American Board of Internal Medicine and currently licensed to practice medicine in New Jersey and New York. He received his Bachelor of Science degree in biochemistry, magna cum laude, from State University of NY at Buffalo. In 1987, Dr. Dunton was awarded The Nellie Westerman Prize from the American Federation for Clinical Research for his research in medical ethics.



Cassandra Klimp., An initial investor and a founding manager of Cytogel Pharma is a partner of Meridian Partners LLC, a technology venture advisory firm and the Classic Motorcar Investment Fund in Connecticut with 30 years of experience in corporate banking, project management and entrepreneurship. Early in her career she was affiliated with US Bancorp in Minneapolis as the corporate lender to multibank holding companies throughout the Midwest. She has performed a broad range of advisory, managerial, financial and project related functions both for profit and non-profit organizations. Ms. Klimp was a long time member of the board of Waveny Care Center and the New Canaan Historical Society. She co-chaired the planning and construction of a state of the art Alzheimer's community at Waveny Care Center that received national recognition. She is a native of Minnesota and holds a BS and post graduate work in the sciences from the University of Minnesota



Joseph J. Rucci, Jr., serves as an outside manager on the Company's Board of Managers and is also a member of the Compensation Committee. Mr. Rucci is founder/member of the Rucci Law Group with offices in Connecticut. He concentrates in the areas of business law, banking and not-for-profit organizations. He is admitted to practice before the Connecticut Bar, the United States District Court for Connecticut and the United States Court of Appeals for the First Circuit, as well as the United States Supreme Court. He is a director and chairman of the Governance Committee of the AmeriCares Foundation, Inc.; a director of the Pear Tree Point School Foundation, Inc.; a member of Rotary International and of the Sovereign Order of Malta. Mr. Rucci has been recognized for his expertise by The Martindale Hubbell Bar Register of Preeminent Lawyers and the National Directory of Who's Who on Executives and Professionals. Mr. Rucci was awarded a Juris Doctorate from the Villanova University School of Law in 1966 and graduated from Fairfield University in 1963.



Frederick W. Telling, Ph.D., Prior to retiring from Pfizer in June 2007 after 30 years, Fred was elected a Corporate Vice President of Pfizer Inc and its Vice President of Corporate Strategic Planning and Policy in October 1994. He oversaw the company's realignment and focus on its human and animal health business - divesting its Food Science and Medical Technology groups, while acquiring Warner Lambert, Pharmacia and various consumer product brands. Concurrently, Fred was responsible for the company's policy development and he represented the company in many industry related outside Boards, including BIO where he served on its Board for over 10 years.

Dr. Telling is currently the Chairman of Oragenics in Tampa, Florida and a Director of Cell Therapeutics Inc. based in Seattle, Washington and Eisai N.A. Inc. in Woodcliff Lake, New Jersey. Fred chairs the Compensation Committee and serves on the Audit Committee of both Cell Therapeutics and Oragenics.

Dr. Telling is a member of the Board of the United Hospital Fund and an emeritus member of the Boards of several organizations with which he remains involved - the National March of Dimes Foundation, EAA, ORBIS, and the Smithsonian National Air & Space Museum. Fred is the President of the T-6 Racing Association and a member of The Metropolitan Club of Washington, DC.

Dr. Telling received his BA from Hamilton College and his Master's of Industrial and Labor Relations and Ph. D. in Economics and Public Policy from Cornell University.



Scientific Advisory Board

Bob A. Rappaport, M.D., Dr. Rappaport joined the Cytogel Advisory Board as a Consultant in 2015, having retired from the FDA in October of 2014. Dr. Rappaport was Director of the Division of Anesthesia, Analgesia, and Addiction Products at the FDA for 12 years where he led a large team of physicians, scientists and regulatory project managers to oversee the investigation, development, approval, continued safety, and safe use of drug products to treat pain and addiction disorders, as well as drug products used in the setting of clinical anesthesia. He was an advocate for the development of novel analgesic, anesthetic and addiction drug products throughout his tenure, and instituted new standards for the study of these drugs. He has also been an active member of the IMMPACT consensus group since its inception. In 2010 he worked within FDA to build the ACTTION (Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks) public-private-partnership, which was initially designed to advance the field of analgesic drug development by improving analgesic clinical study design, conduct and analysis. This highly successful initiative was later expanded to include improving the study and development of anesthetics, and drugs to treat addiction and peripheral neuropathy. Dr. Rappaport was centrally involved with the FDA's continued efforts to encourage and assist in the development of abuse-deterrent opioid formulations, and with his staff he completed an updated guidance for the pharmaceutical industry on the development of analgesic drug products. In 2013, Dr. Rappaport received the Agency's Lifetime Achievement Award for his contributions to the anesthesia, analgesia, and addiction fields by accelerating the discovery and development of new drugs with improved efficacy and safety.

Dr. Rappaport graduated from and completed his medical training at The George Washington University School of Medicine and Health Sciences, and is board certified in neurology and sleep medicine. Dr. Rappaport received the 2015 John and Emma Bonica Public Service Award at the annual meeting of the American Pain Society. The Bonica Award recognizes distinguished contributions to the field of pain through public education, dissemination of information, public service, or other efforts that further knowledge about pain.



Jack Uetrecht, M.D., Ph.D., Dr. Uetrecht has joined the Company's Scientific Advisory Board. He is Professor of Pharmacy, Medicine and Pharmacology, at the University of Toronto and Sunnybrook Health Science Centre. He was the Canada Research Chair in Adverse Drug Reactions from 2001 to 2015 (the maximum is two 7 year terms). Dr. Uetrecht is the past recipient of Pharmaceutical Manufacturers Association Foundation Faculty Development Award and the Janssen-Ortho Award for Research. He has spent his whole career of more than 30 years on the study of idiosyncratic drug reactions, including both basic mechanistic studies and reviewing clinical cases. His background includes a Ph.D. in organic chemistry, an M.D., an internal medicine residency, and a clinical pharmacology fellowship.



Lynn R. Webster, M.D., F.A.C.P.M., F.A.S.A.M., Dr. Webster, Vice President, Scientific Affairs, PRA, is a leading pain physician and researcher with a focus on the management of complex pain problems and addiction. He has long been an advocate for patients suffering from chronic pain, and he has fought for better education and safer therapies to address the twin crises of chronic pain and addiction in America. He is dedicated to minimizing the potential for harm from pain medications.

Dr. Webster earned his doctorate of medicine from the University of Nebraska and completed his residency in the University of Utah's Department of Anaesthesiology. He is board certified in anaesthesiology, pain medicine, and addiction medicine. He lectures extensively and has authored more than 300 scientific publications. Dr. Webster is a senior editor of Pain Medicine and former editor of the sections on Neuromodulation and Opioids, Substance Abuse and Addiction. He maintains a loyal base of thousands of followers via his social networks and his blog at www.thepainfultruthbook.com.

Dr. Webster is vice president of Scientific Affairs for PRA, a leading clinical research organization that operates in more than 80 countries. Dr. Webster is a past president of the American Academy of Pain Medicine (AAPM). He is the author of The Painful Truth: What Chronic Pain Is Really Like and Why It Matters to Each of Us (Oxford University Press) and co-producer of the documentary, "The Painful Truth," airing on public television stations throughout the United States.



William K. Schmidt, Ph.D. President, NorthStar Consulting, LLC Dr. Schmidt is head of NorthStar Consulting, LLC, which specializes in providing advice on preclinical and clinical studies of novel analgesic drugs. At NorthStar, Dr. Schmidt serves as an expert on pain medicine pharmaceutical development and has lead projects throughout North America, Europe, Asia, Latin America, and Australia. Dr. Schmidt currently sits on the Scientific or Medical Advisory Boards of 3 biotech companies and one internet medical publishing company. Dr. Schmidt was a key member of the team leading to the clinical development, NDA filing, and FDA approval of Entereg® (alvimopan), a peripherally-acting opioid antagonist. Dr. Schmidt led Phase 1b through Phase 2b clinical trials that lead to the approval of Acelex® (polmacoxib) in South Korea. Dr. Schmidt is the Parliamentarian and a Past-President of the Eastern Pain Association, the largest regional affiliate of the American Pain Society. He received the John J. Bonica award for the development of new analgesics and his sustained contributions to the educational efforts of the Eastern Pain Association in 2014. He is the co-editor of "Pain: Current Understanding, Emerging, Therapies, and Novel Approaches to Drug Discovery" (Marcel Dekker, 2003). Dr. Schmidt received his Ph.D. in Pharmacology from the University of California, San Francisco. Following his postdoctoral fellowship at Boston University School of Medicine, Dr. Schmidt joined DuPont Pharmaceuticals (later the DuPont Merck Pharmaceutical Company) where he helped to develop nalbuphine (Nubain®), naltrexone (Trexan®, ReVia®) and the oxycodone-ibuprofen formulation used in Combunox. Dr. Schmidt continues to chair the annual Arrowhead Pain Summit (2010-2019) and the Pharmaceutical Roundtable / Innovations in Pain Research for the Eastern Pain Association (2003-2019).